Inflammatory Response Research, Inc.

11:30 AM - 11:45 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
IRR is a science-based drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions. Products under development incorporate the uniquely synergistic anti-inflammatory combination of levocetirizine (Xyzal®) and montelukast (Singulair®) at specific doses / administration.

In 2022, IRR received a significant Congressionally Directed Medical Research Program (CDMRP-DOD) award to facilitate development of a ‘First Response’, in-theater, combat injectable to mitigate inflammation following traumatic brain injury. The grant provides funding for formulation of the injectable as well as large animal study at PENN; replete with 9 biomarkers of inflammation and advanced neuroimaging. Upon advice from FDA consultants, the clinically discovered therapeutic has the potential to proceed directly to a Phase III clinical trial following completion of limited toxicology and pharmacokinetic analyses. Anticipated timeline to approval is 36 months.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
First Response Therapeutic to Treat Traumatic Brain Injury
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Executive Officer
Inflammatory Response Research, Inc.